These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 989253)

  • 21. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.
    Juma FD; Rogers HJ; Trounce JR
    Eur J Clin Pharmacol; 1981; 19(6):443-51. PubMed ID: 7250178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on the pharmacokinetics of cyclophosphamide in sheep.
    Schaumlöffel E; Habermehl A; Brock N; Schneider B
    Arzneimittelforschung; 1973 Apr; 23(4):491-500. PubMed ID: 4740226
    [No Abstract]   [Full Text] [Related]  

  • 23. The influence of alkylants, antimetabolites and chloroquine on oxydative biotransformation reactions and on the excretion of ascorbic acid in the rat.
    Traeger A; Bauer B; Klinger W; Ankermann H
    Acta Biol Med Ger; 1973; 30(3):423-34. PubMed ID: 4800889
    [No Abstract]   [Full Text] [Related]  

  • 24. Decreased half life of cyclophosphamide in patients under continual treatment.
    D'Incalci M; Bolis G; Facchinetti T; Mangioni C; Morasca L; Morazzoni P; Salmona M
    Eur J Cancer (1965); 1979 Jan; 15(1):7-10. PubMed ID: 421718
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics of cyclophosphamide after prolonged low dose treatment in ovarian cancer patients.
    D'Incalci M; Facchinetti T; Bolis G; Mangioni C; Morasca L
    Eur J Drug Metab Pharmacokinet; 1979; 4(2):83-5. PubMed ID: 114397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil.
    Jamieson D; Lee J; Cresti N; Jackson R; Griffin M; Sludden J; Verrill M; Boddy AV
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):667-74. PubMed ID: 25055937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of methotrexate.
    Huffman DH; Wan SH; Azarnoff DL; Hogstraten B
    Clin Pharmacol Ther; 1973; 14(4):572-9. PubMed ID: 4723265
    [No Abstract]   [Full Text] [Related]  

  • 28. [On the activation of cyclophosphamide in man and animals].
    Brock N
    Prensa Med Argent; 1971 Jan; 57(48):2170-8. PubMed ID: 5091404
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of liver failure on the pharmacokinetics of cyclophosphamide.
    Juma FD
    Eur J Clin Pharmacol; 1984; 26(5):591-3. PubMed ID: 6468474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WR-2721: enhanced chemoprotection by increasing cyclophosphamide activation with phenobarbitol.
    Glover DJ; Yuhas JM; Glick JH
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):571-4. PubMed ID: 6286555
    [No Abstract]   [Full Text] [Related]  

  • 31. Half-life of oxazaphosphorines in biological fluids.
    Sladek NE; Powers JF; Grage GM
    Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of cyclophosphamide and methotrexate on the 'field effect' or unresponsiveness observed in the rat and mouse GvHR.
    Levy L
    Agents Actions; 1975 Aug; 5(3):268-71. PubMed ID: 27086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.
    Hinchliffe M; McNally NJ; Stratford MR
    Br J Cancer; 1983 Sep; 48(3):375-83. PubMed ID: 6615699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PLasma half-life and urinary excretion of cyclophosphamide in children.
    Sladek NE; Priest J; Doeden D; Mirocha CJ; Pathre S; Krivit W
    Cancer Treat Rep; 1980; 64(10-11):1061-6. PubMed ID: 7459891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic and pharmacokinetic measurements of antitumor agents.
    Mellett LB
    Clin Pharmacol Ther; 1974 Jul; 16(1):230-42. PubMed ID: 4210526
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetic interactions of cyclophosphamide and 5-fluorouracil with methotrexate in an animal model.
    de Bruijn EA; Driessen O; Leeflang P; van den Bosch N; van Strijen E; Slee PH; Hermans J
    Cancer Treat Rep; 1986 Oct; 70(10):1159-65. PubMed ID: 3756938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of operative treatment, chemotherapy, and oestrogens on the phagocytic activity of the reticuloendothelial system.
    Berstad T; Liavåg I; Tamsfoss S
    Acta Chir Scand; 1972; 138(6):557-61. PubMed ID: 5084297
    [No Abstract]   [Full Text] [Related]  

  • 38. The CMF-regimen. Modulation of cyclophosphamide uptake and clearance by methotrexate and fluorouracil.
    De Bruijn EA; Geng Y; Hermans J; Driessen O
    Int J Cancer; 1990 May; 45(5):935-9. PubMed ID: 2335396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The effects of cytostatic agents - methotrexate, actinomycin-D and cyclophosphamide - on in vitro metabolism of human placenta from early pregnancy (author's transl)].
    Nagy P; Csaba IF; Szilágyi A
    Z Geburtshilfe Perinatol; 1982; 186(2):101-3. PubMed ID: 7202294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interchangeability of methotrexate and cyclophosphamide as inhibitors of allergic contact dermatitis in the guinea pig.
    Maibach HI; Maguire HC
    Int Arch Allergy Appl Immunol; 1969; 35(6):535-43. PubMed ID: 5785598
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.